SEC Form 4Coverage since Jun 16, 2026
$NRSN insider trading
Over the last 12 months, NeuroSense Therapeutics insiders reported 2 buys totaling $400K and no sales across SEC Form 4 filings.
- Bought · 12m
- $400K 2 events
- Sold · 12m
- — 0 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $NRSN · 12Mvia TradingView
Top insiders · 12m
Ben-Noon AlonChief Executive Officer1× · $200K
Eisenberg OrChief Financial Officer1× · $200K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Ben-Noon AlonChief Executive Officer · O | ▲ Buy | 250,000 | $0.8 | $200K | +5.8% | — |
| Jun 16, 2026 | Eisenberg OrChief Financial Officer · O | ▲ Buy | 250,000 | $0.8 | $200K | +19.9% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NRSN feed.